Director Parsa Kiai filed a Form 4 with the SEC on November 20, 2026, disclosing purchases of Medifast Inc common stock on November 18 and November 19, 2026, through affiliated investment funds.

Key Highlights

  • Four transactions reported: Kiai disclosed two purchase transactions on November 18, 2026, and two on November 19, 2026, all coded "P" (purchase).
  • November 18 purchases: 8,630 shares acquired at an average price of $12.1613 and 256 shares at an average price of $12.1613, with actual prices ranging from $12.06 to $12.20 per share.
  • November 19 purchases: 82,700 shares acquired at an average price of $12.0464 and 2,450 shares at an average price of $12.0464, with actual prices ranging from $11.855 to $12.15 per share.
  • Post-transaction holdings: Following the reported transactions, beneficial ownership stands at 804,221 shares held through Steamboat Capital Partners Master Fund, LP, and 23,795 shares held through Steamboat Capital Partners II, LP.
  • Indirect ownership: All shares are held indirectly; Kiai disclaims beneficial ownership except to the extent of his pecuniary interest.
  • Issuer: Medifast Inc, traded as NYSE:MED.

Kiai's Purchases Through Steamboat Capital Funds in November 2026

According to the filing, Parsa Kiai, identified as a director of Medifast Inc (NYSE:MED), reported purchases of common stock across two trading days. On November 18, 2026, 8,630 shares were acquired at an average price of $12.1613 through Steamboat Capital Partners Master Fund, LP (referred to in the filing as "Master"), and 256 shares were acquired at the same average price through Steamboat Capital Partners II, LP (referred to as "II"). The filing notes that actual prices for November 18 purchases ranged from $12.06 to $12.20 per share.

On November 19, 2026, an additional 82,700 shares were acquired through Master at an average price of $12.0464, and 2,450 shares were acquired through II at the same average price. The filing states that actual prices for November 19 purchases ranged from $11.855 to $12.15 per share. The reporting person undertook to provide full information on the number of shares and prices at which each transaction was effected upon request.

The filing explains the ownership structure: Steamboat Capital Partners GP, LLC is the general partner of both Master and II, and Kiai is the Managing Member of both the GP entity and Steamboat Capital Partners, LLC, the registered investment adviser that holds investment discretion. The filing states that "Kiai disclaims beneficial ownership of securities reported hereon except to the extent of his pecuniary interest therein." All reported ownership is indirect. No derivative securities transactions were reported.

What Was Disclosed

Parsa Kiai, a Medifast director, disclosed indirect purchases of a combined 94,036 shares of Medifast common stock on November 18 and 19, 2026, through two affiliated funds, at average prices of $12.1613 and $12.0464 respectively, bringing total indirect beneficial ownership to 828,016 shares across both funds.